icon-folder.gif   Conference Reports for NATAP  
 
  18th European AIDS Conference
October 27th-30th, 2021
Online & United Kingdom
Back grey_arrow_rt.gif
 
 
 
European Phase 3/3b Experience With Long-Acting Cabotegravir
and Rilpivirine: Efficacy, Safety, and Virologic Outcomes

 
 
  EACS 2021 Oct 27-30
 
Jean-Michel Molina1, M. Luisa Montes2, Stefan Esser3, Nathalie De Castro1, Parul Patel4, Samia Dakhia5, Joseph W. Polli4, Louise Garside6, Ronald D'Amico4, Christine Talarico4, Veerle Van Eygen7, Kati Vandermeulen7, William R. Spreen4, Michael Aboud5, Matthew Bosse8 1University of Paris Diderot, Saint-Louis Hospital, Paris, France; 2La Paz University Hospital, Madrid, Spain; 3University Hospital Duisburg-Essen, Germany; 4ViiV Healthcare, Research Triangle Park, NC, United States; 5ViiV Healthcare, Brentford, United Kingdom; 6GlaxoSmithKline, London, United Kingdom; 7Janssen Research & Development, Beerse, Belgium; 8ViiV Healthcare, San Diego, CA, United States

1101211

1101212

1101213

1101214

1101215

1101216

1101217